S'abonner

Combined Role of Troponin and Natriuretic Peptides Measurements in Patients With Covid-19 (from the Cardio-COVID-Italy Multicenter Study) - 24/02/22

Doi : 10.1016/j.amjcard.2021.11.054 
Annamario Iorio, MD a, Carlo Mario Lombardi, MD b, , Caludia Specchia, PHD c, Marco Merlo, MD d, Vincenzo Nuzzi, MD d, Ilenia Ferraro, MD a, Giulia Peveri, Msc c, e, Chiara Oriecuia, MSc c, Andrea Pozzi, MD a, Riccardo Maria Inciardi, MD b, Valentina Carubelli, MD, Phd b, Antonio Bellasi, MD f, Claudia Canale, MD g, Rita Camporotondo, MD h, Francesco Catagnano, MD h, Laura Dalla Vecchia, MD i, Stefano Giovinazzo, MD g, Gloria Maccagni, MD j, Massimo Mapelli, MD k, Davide Margonato, MD h, Luca Monzo, MD l, Giovanni Provenzale, MD m, Filippo Sarullo, MD n, Daniela Tomasoni, MD b, Pietro Ameri, MD, PhD g, Massimiliano Gnecchi, MD h, Sergio Leonardi, MD h, Piergiuseppe Agostoni, MD, PhD k, Stefano Carugo, MD m, Gian Battista Danzi, MD j, Marco Guazzi, MD, Phd o, Maria Teresa La Rovere, MD p, Andrea Mortara, MD q, Massimo Piepoli, MD, PhD r, Italo Porto, MD, Phd g, Maurizio Volterrani, MD, Phd s, Gianfranco Sinagra, MD d, Michele Senni, MD a, Marco Metra, MD b
a Cardiology Unit, Cardiovascular Department, Papa Giovanni XXIII Hospital–Bergamo, Bergamo, Italy 
b Cardiology, ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy 
c Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy 
d Cardiothoracovascular Department, Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI), University of Trieste, Italy 
e Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy 
f Innovation and Brand Reputation Unit, Papa Giovanni XXIII Hospital, Bergamo, Italy 
g Department of Internal Medicine, IRCCS Ospedale Policlinico San Martino–IRCCS Italian Cardiovascular Network, University of Genova, Genoa, Italy 
h Cardiology Department and Fondazione IRCCS Policlinico S. Matteo, University of Pavia 
i Department of Cardiology, Istituti Clinici Scientifici Maugeri, IRCCS, Istituto Scientifico di Milano, Milan, Italy 
j Division of Cardiology, Civil Hospital, Cremona, Italy 
k Centro Cardiologico Monzino, IRCCS, Milan, Italy and Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy 
l Istituto clinico Casal Palocco, Policlinico Casilino, Rome, Italy 
m Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Internal Medicine Department, Cardiac Unit, University of Milan, Italy 
n Cardiovascular Rehabilitation Unit, Buccheri La Ferla Fatebenefratelli Hospital, Palermo, Italy 
o Division of Cardiology, Ospedale San Paolo, ASST Santi Paolo e Carlo, University of Milan, Milan, Italy 
p Dipartimento di Cardiologia, Istituti Clinici Scientifici Maugeri, IRCCS, Istituto Scientifico di Montescano, Pavia, Italy 
q Cardiology Department, Policlinico di Monza, Monza, Italy 
r Institute of Life Sciences, Sant'Anna School of Advanced Studies, Pisa, Italy 
s Department of Cardiovascular and Respiratory Sciences, IRCCS, San Raffaele Pisana Rome, Rome, Italy 

Corresponding author: Tel: +393383225230, Fax: +393700359.

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Résumé

Data concerning the combined prognostic role of natriuretic peptide (NP) and troponin in patients with COVID-19 are lacking. The aim of the study is to evaluate the combined prognostic value of NPs and troponin in hospitalized COVID-19 patients. From March 1, 2020 to April 9, 2020, consecutive patients with COVID-19 and available data on cardiac biomarkers at admission were recruited. Patients admitted for acute coronary syndrome were excluded. Troponin levels were defined as elevated when greater than the 99th percentile of normal values. NPs were considered elevated if above the limit for ruling in acute heart failure (HF). A total of 341 patients were included in this study, mean age 68 ± 13 years, 72% were men. During a median follow-up period of 14 days, 81 patients (24%) died. In the Cox regression analysis, patients with elevated both NPs and troponin levels had higher risk of death compared with those with normal levels of both (hazard ratio 2.94; 95% confidence interval 1.31 to 6.64; p = 0.009), and this remained significant after adjustment for age, gender, oxygen saturation, HF history, and chronic kidney disease. Interestingly, NPs provided risk stratification also in patients with normal troponin values (hazard ratio 2.86; 95% confidence interval 1.21 to 6.72; p = 0.016 with high NPs levels). These data show the combined prognostic role of troponin and NPs in COVID-19 patients. NPs value may be helpful in identifying patients with a worse prognosis among those with normal troponin values. Further, NPs’ cut-point used for diagnosis of acute HF has a predictive role in patients with COVID-19.

Le texte complet de cet article est disponible en PDF.

© 2021  Elsevier Inc. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 167

P. 125-132 - mars 2022 Retour au numéro
Article précédent Article précédent
  • Temporal Trends in Use of Complementary Therapies Among Patients With Cardiovascular Disorders
  • Kavita Prasad, Abhiram Prasad, Merit George, Gurpreet S. Sandhu, Jose R. Medina Inojosa, Anjali Bhagra, Saswati Mahapatra, Tanya M. Petterson, Kandace A. Lackore, Ivana T. Croghan, Brent A. Bauer, Dietlind L. Wahner-Roedler
| Article suivant Article suivant
  • Usefulness of Combined Renin-Angiotensin System Inhibitors and Diuretic Treatment In Patients Hospitalized with COVID-19
  • Alberto Palazzuoli, Kristen M. Tecson, Marco Vicenzi, Fabrizio D'Ascenzo, Gaetano Maria De Ferrari, Silvia Monticone, Gioel G. Secco, Guido Tavazzi, Giovanni Forleo, Paolo Severino, Francesco Fedele, Francesco De Rosa, Peter A. McCullough

Bienvenue sur EM-consulte, la référence des professionnels de santé.

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.